Bayer’s experimental PET scan detected 94% of cardiac amyloidosis cases. Can it identify the disease earlier?
Bayer's amyloidosis PET tracer showed 94% sensitivity in Phase III. New HFSA analyses examine earlier diagnosis and finerenone treatment gaps.